SRGAP2D: A Potential Drug Target and Biomarker (G100996712)

Target Name: SRGAP2D

NCBI ID: G100996712

SRGAP2D

Other Name(s): SLIT-ROBO Rho GTPase activating protein 2D (pseudogene)

SRGAP2D: A Potential Drug Target and Biomarker

Sodium channels play a crucial role in many physiological processes, including muscle contractions, nerve signals, and brain function. They are also involved in pain perception and neurodegenerative diseases. The sodium channel blocker SRGAP2D has been identified as a potential drug target and biomarker for several diseases, including Alzheimer's disease, Parkinson's disease, and epilepsy.

SRGAP2D is a protein that is expressed in many different tissues, including the brain, heart, and muscle. It is a member of the TRPV4 receptor family, which is responsible for mediating pain, inflammation, and other physiological processes. The TRPV4 receptor is activated by low levels of calcium ions, which can be generated by sodium channels.

Studies have shown that SRGAP2D is involved in many different cellular processes, including neurotransmitter release, ion channels, and cell signaling. It has been shown to interact with many different proteins, including the neurotransmitter GABA, which is involved in many important cellular processes, including mood regulation, anxiety, and pain perception.

In addition to its role in neurotransmitter release, SRGAP2D has also been shown to be involved in modulating ion channels. It has been shown to interact with the sodium channel subunit alpha-2 (Na+/K+-ATPase), which is responsible for regulating the movement of sodium and potassium ions into and out of cells. This interaction between SRGAP2D and Na+/K+-ATPase suggests that SRGAP2D may be a useful drug target for treating conditions that involve ion channel dysfunction, such as epilepsy.

Another study has shown that SRGAP2D is involved in cell signaling pathways that are involved in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These studies suggest that SRGAP2D may be a useful biomarker for these diseases, as well as for other neurological disorders.

In addition to its potential drug-target and biomarker properties, SRGAP2D is also of interest due to its structural characteristics. It is a large protein that contains multiple domains, including an N-terminal transmembrane domain, a catalytic domain, and a C-terminal region that is involved in interactions with other proteins. The N-terminal transmembrane domain is responsible for allowing SRGAP2D to interact with membrane receptors, while the catalytic domain is responsible for its catalytic activity.

The catalytic domain of SRGAP2D is known to contain a unique type of zinc ion-binding site that is involved in the regulation of ion channels. This zinc ion-binding site is located in the N-terminus of the catalytic domain and is responsible for the binding of zinc ions to the protein. This interaction between zinc ions and the catalytic domain of SRGAP2D suggests that SRGAP2D may be a useful drug target for treating conditions that involve ion channel dysfunction, such as epilepsy.

In conclusion, SRGAP2D is a protein that is expressed in many different tissues and is involved in a wide range of cellular processes. Its interaction with the neurotransmitter GABA and its involvement in modulating ion channels suggest that it may be a useful drug target and biomarker for many different neurological disorders, including Alzheimer's disease, Parkinson's disease, and epilepsy. Its structural characteristics also suggest that it may be a useful target for treating conditions that involve ion channel dysfunction. Further research is needed to fully understand the role of SRGAP2D in these and other diseases.

Protein Name: SLIT-ROBO Rho GTPase Activating Protein 2D (pseudogene)

The "SRGAP2D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SRGAP2D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets